Drugs / TNS9.3.55
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01639690 | Jul 2012 → Jul 2027 expected | beta-thalassemia major | San Rocco Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNS9.3.55 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639690 ↗ |
| Action | Restore | “These cells are then treated so they have the corrected gene for making normal hemoglobin.” NCT01639690 ↗ |
| Modality | Cell therapy | “autologous CD34+ cells transduced with the TNS9.3.55 lentiviral globin vector” PMID 34980909 ↗ Jan 2022 |
| Route | Intravenous | “These treated cells are given back to the patient through an injection (shot) in the vein.” NCT01639690 ↗ |